Nampt is a promising target for the treatment of hematological malignancies. Here, we investigated the cytotoxic activity of APO866, a potent, reversible Nampt inhibitor, in primary acute myelogenous leukemia and in chronic lymphocytic leukemia cells. 10 nM APO866 exhibited limited killing of primary leukemia cells with specific death rates after four days of incubation that typically ranged between 10% and 50%. We conclude that, although APO866 is a promising agent for treating human leukemias, further studies are warranted to understand its mode of action, as well as its potential in combination treatments.
APO866 activity in hematologic malignancies: a preclinical in vitro study.
CEA, MICHELE;ZOPPOLI, GABRIELE;BRUZZONE, SANTINA;FRUSCIONE, FLORIANA;MORAN, EVA;GARUTI, ANNA;ROCCO, ILARIA;CIRMENA, GABRIELLA;PIERRI, IVANA;CAGNETTA, ANTONIA;FERRANDO, FABIO;GHIO, RICCARDO;GOBBI, MARCO;BALLESTRERO, ALBERTO;PATRONE, FRANCO;NENCIONI, ALESSIO
2009-01-01
Abstract
Nampt is a promising target for the treatment of hematological malignancies. Here, we investigated the cytotoxic activity of APO866, a potent, reversible Nampt inhibitor, in primary acute myelogenous leukemia and in chronic lymphocytic leukemia cells. 10 nM APO866 exhibited limited killing of primary leukemia cells with specific death rates after four days of incubation that typically ranged between 10% and 50%. We conclude that, although APO866 is a promising agent for treating human leukemias, further studies are warranted to understand its mode of action, as well as its potential in combination treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
